Amarin Corp Plc (AMRN)

[MedResCollab]

Could a generic Vascepa make the same claim? Yes. Why? It delivers the same or better API, which is in this case EPA.

There’s no escaping it. If increasing EPA serum levels to or beyond a certain level (the entire point and only relevance to taking Vascepa) reduces your risk of ASCVD, then that can be had in a number of ways, from a number of different supplements. Amarin themselves admit this when they erroneously state “it would take X number of fish oil pills to get that much EPA” in one of their adverts.

Think of the statin market. Once it was known that HMG-CoA reductase inhibitors reduced risk of ASCVD, lots of different kinds came out, all under the same category (HMG-CoA reductase inhibitors). There was a link in the reduction of LDL-C, and theories that HMG-CoA reductase inhibitors that lowered LDL-C more were more effective than those that didn’t as much. Which is probably true. By extension, these are all EPA supplements. Vascepa really is an EPA supplement. It’s designed to get EPA into your blood. So these are all the same kind of “drug.” Think of Vacsepa as the 1.0 lovastatin, and OmegaVia EPA as the better, 2.0 atorvastatin. Same concept.

Regards,
-MRC